GlycoMimetics, Inc (GLYC)

Etorro trading 970x250

About GlycoMimetics, Inc

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company’s drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland. Address: 9708 Medical Center Drive, Rockville, MD, United States, 20850

GlycoMimetics, Inc News and around…

Latest news about GlycoMimetics, Inc (GLYC) common stock and company :

Two GlycoMimetics Posters at 63rd ASH Annual Meeting Highlight Potential of GMI-1359, a Dual Antagonist of CXCR4 and E-selectin
13 Dec, 2021 FinancialContent

GlycoMimetics, Inc. (Nasdaq: GLYC) this week at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta presented two posters providing support for targeting both CXCR4 and E-selectin with GMI-1359, the Company’s dual antagonist of CXCR4 and E-selectin, as a novel treatment strategy for patients with AML.

NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule
06 Dec, 2021 FinancialContent

GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company, announced today that the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and the Alliance for Clinical Trials in Oncology, have completed enrollment of 267 patients in the Phase 2 portion of the adaptive Phase 2/3 trial evaluating whether uproleselan improves overall survival in newly diagnosed patients 60 years or older with acute myeloid leukemia (AML). The randomized, controlled trial is evaluating the addition of uproleselan, GlycoMimetics’ investigational, first-in-class, targeted antagonist of E-selectin, to a standard cytarabine/daunorubicin regimen (7&3) in older adults with previously untreated AML who are suitable for intensive chemotherapy. Completion of enrollment now sets the stage for a planned evaluation of the Phase 2 portion of the trial to determine whether the prespecified threshold for continuing to Phase 3 has been met based on event-free survival (EFS). Geoffrey Uy, M.D., Professor of Medicine, Washington University School of Medicine in St. Louis, is the trial’s Principal Investigator. GlycoMimetics and NCI are collaborating on the development of uproleselan under a Cooperative Research and Development Agreement.

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
25 Nov, 2021 FinancialContent

GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on November 22, 2021 of a non-qualified stock option award to purchase an aggregate of 100,000 shares to one new employee. The award was granted as an inducement equity award outside of the Company’s 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and was made as an inducement material to the acceptance of employment with the Company by the new employee.

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML
23 Nov, 2021 FinancialContent

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). Apollomics’ Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study. The Phase 3 clinical trial is part of a randomized, double-blind, placebo controlled, bridging study program that will evaluate the efficacy of uproleselan in combination with chemotherapy, compared to chemotherapy alone, for treating relapsed/refractory AML, in Chinese patients. The trial will enroll approximately 140 adult patients with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy.

GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs
22 Nov, 2021 FinancialContent

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs. Dr. DeLuca is a veteran regulatory expert who has previously led the strategy-formation and execution of multiple global NDA submissions and product registrations. Most recently she was the head of regulatory affairs at Nuvation Bio and a member of its executive leadership team.

GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML)
15 Nov, 2021 FinancialContent

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced completion of enrollment of its pivotal Phase 3 trial evaluating uproleselan in addition to a standard chemotherapy regimen in patients with relapsed/refractory AML. A total of 388 patients across 70 sites in nine countries has now been randomized in the clinical trial, which has a primary endpoint of overall survival, not censored for transplant. GlycoMimetics reiterates its guidance that, based upon current projections, it expects topline results after year-end 2022.

Benzinga's Top Ratings Upgrades, Downgrades For November 12, 2021
12 Nov, 2021 FinancialContent

Upgrades For Blink Charging Co (NASDAQ:BLNK), Roth Capital upgraded the previous rating of Neutral to Buy. In the third ...

18 Stocks Moving In Friday's Pre-Market Session
12 Nov, 2021 FinancialContent

Gainers NuZee, Inc. (NASDAQ: NUZE) rose 30.3% to $6.89 in pre-market trading after jumping around 165% on Thursday. NuZee ...

GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
11 Nov, 2021 FinancialContent

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that two abstracts relating to GMI-1359, the Company’s dual antagonist of CXCR4 and E-selectin, have been accepted for poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 11-14, 2021.

GlycoMimetics to Present at Two Upcoming Healthcare Investor Conferences
09 Nov, 2021 FinancialContent

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Harout Semerjian will present an overview of the company at the upcoming Stifel 2021 Virtual Healthcare Conference on Monday, November 15 and the Jefferies London Healthcare Conference on Wednesday, November 17. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows:

GlycoMimetics (NASDAQ:GLYC) investors are sitting on a loss of 84% if they invested three years ago
09 Nov, 2021 Yahoo! Finance

Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So spare a thought for...

Analysts Expect 24% Gains Ahead For IEIH
03 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

GlycoMimetics, inc (GLYC) Q3 2021 Earnings Call Transcript
02 Nov, 2021 FinancialContent

GLYC earnings call for the period ending September 30, 2021.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
02 Nov, 2021 FinancialContent

Gainers Bone Biologics (NASDAQ:BBLG) shares rose 33.57% to $7.32 during Tuesday's pre-market session. The ...

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2021
02 Nov, 2021 FinancialContent

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended September 30, 2021 and highlighted recent events. Cash and cash equivalents at September 30, 2021 were $101.9 million.

GlycoMimetics to Report Third Quarter Financial Results on November 2, 2021
26 Oct, 2021 FinancialContent

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Tuesday, November 2, 2021, at 8:30 a.m. ET.

Peek Under The Hood: ITOT Has 13% Upside
29 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.

GlycoMimetics' Lead Candidate Data Published In An Online Journal
24 Sep, 2021 FinancialContent

GlycoMimetics Inc(NASDAQ: GLYC) has announced that efficacy and safety data from a Phase 1/2 study of uproleselan ...

Efficacy and Safety Data for GlycoMimetics’ Lead Investigational Drug Uproleselan Published in BLOOD
23 Sep, 2021 FinancialContent

Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics’ lead investigational drug, were published online September 16, 2021 in the journal BLOOD. In the manuscript, scientists highlight an analysis of minimal residual disease (MRD) and report an MRD negative rate of 69 percent in trial participants with relapsed/refractory acute myeloid leukemia (AML), indicating an enhanced depth of response following addition of uproleselan to salvage therapy. The paper also confirms that uproleselan can be safely combined with an intensive salvage chemotherapy regimen without adding toxicity in both relapsed/refractory and in newly diagnosed older AML patients and builds upon results first reported at the 2018 ASH Meeting. The paper’s lead author, Daniel J. DeAngelo, M.D., Ph.D., of the Dana Farber Cancer Institute in Boston, noted that “the combination of uproleselan with a standard salvage regimen of mitoxantrone, etoposide and cytarabine (MEC) demonstrated a substantial improvement in both response rate and survival in relapsed/refractory AML patients compared to previously reported results with chemotherapy alone.”

Are Institutions Heavily Invested In GlycoMimetics, Inc.'s (NASDAQ:GLYC) Shares?
10 Sep, 2021 Yahoo! Finance

The big shareholder groups in GlycoMimetics, Inc. ( NASDAQ:GLYC ) have power over the company. Institutions often own...

GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference
08 Sep, 2021 FinancialContent

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Harout Semerjian will present at the upcoming H.C. Wainwright & Co 23rd Annual Global Investment Virtual Conference taking place September 13-15, 2021. The presentation will be available on the company’s website at the “Investors” tab for 30 days, beginning Monday, September 13 at 7:00 a.m. EDT.

Implied VHT Analyst Target Price: $286
27 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $285.65 per unit.

Implied Volatility Surging for GlycoMimetics (GLYC) Stock Options
23 Aug, 2021 Yahoo! Finance

Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

GlycoMimetics, inc (GLYC) Q2 2021 Earnings Call Transcript
07 Aug, 2021 FinancialContent

GLYC earnings call for the period ending June 30, 2021.

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Thursday
05 Aug, 2021 FinancialContent

During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest ...

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

GlycoMimetics, Inc (GLYC) is a NASDAQ Common Stock listed in , ,

970x250